新辅助化疗对乳腺癌患者雌激素受体、孕激素受体、人表皮生长因子受体-2表达的影响
|
摘要
乳腺癌作为全球范围内发病率较高的恶性肿瘤,对其分子分型的研究一直在进行,雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(C-erbB-2,HER2/neu)是已被广泛认可的乳腺癌的重要生物学标志物,对乳腺癌的分型诊断、治疗方案的制定及预后评价均具有重要意义。乳腺癌新辅助化疗(NAC)可有效控制肿瘤,针对新辅助化疗前后ER、PR及C-erbB-2的表达情况,国内外进行了大量的相关研究,但均未达成一致结论。
Breast cancer is a kind of malignant tumor with high incidence rate in all over the world and the studies of its molecular classifications have been always conducting. The estrogen receptor( ER),progesterone receptor( PR) and human epidermal growth factor receptor-2( C-erb B-2,HER2/neu) as important biological markers of breast cancer have been widely recognized,which are of great significance for classification,diagnosis,treatment and prognosis evaluation. The neoadjuvant chemotherapy( NAC) of breast cancer can effectively control the tumor. For the expression of ER,PR and C-erbB-2 before and after neoadjuvant chemotherapy of breast cancer,a large number of relevant researches have been studied at home and abroad,but all have failed to agree on same conclusions.
Breast cancer is a kind of malignant tumor with high incidence rate in all over the world and the studies of its molecular classifications have been always conducting. The estrogen receptor( ER),progesterone receptor( PR) and human epidermal growth factor receptor-2( C-erb B-2,HER2/neu) as important biological markers of breast cancer have been widely recognized,which are of great significance for classification,diagnosis,treatment and prognosis evaluation. The neoadjuvant chemotherapy( NAC) of breast cancer can effectively control the tumor. For the expression of ER,PR and C-erbB-2 before and after neoadjuvant chemotherapy of breast cancer,a large number of relevant researches have been studied at home and abroad,but all have failed to agree on same conclusions.
引文
[1]Ramteke P,Seenu V,Prashad R,et al.Alteration in steroid hormone and Her-2/neu receptor status following neoadjuvant chemotherapy in locally advanced breast cancer:Experience at a tertiary care centre in India[J].Indian J Cancer,2016,53(3):366-371.
[2]Catsburg C,Miller AB,Rohan TE.Adherence to cancer prevention guidelines and risk of breast cancer[J].Int J Cancer,2014,135(10):2444-2452.
[3]Aytekin A,Karatas F,Sahin S,et al.Clinicopathological features of patients with breast cancer aged 70 years or over[J].J BUON,2017,22(1):200-207.
[4]Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CACancer J Clin,2016,66(1):7-30.
[5]卢玮冬,许震,陆筱灵,等.培美曲塞联合顺铂治疗经蒽环类和紫杉类一线治疗失败的晚期转移性乳腺癌的疗效观察[J].国际肿瘤学杂志,2014,41(10):797-798.
[6]Wahler J,Suh N.Targeting HER2 positive breast cancer with chemopreventive agents[J].Curr Pharmacol Rep,2015,1(5):324-335.
[7]Petrelli F,Viale G,Cabiddu M,et al.Prognostic value of different cutt-off levels of Ki-67 in breast cancer:a systematic review and metaanalysis of 64,196 patients[J].Breast Cancer Res Treat,2015,153(3):477-491.
[8]吕锋,黄小娥,鲁科斌.蒽环类与紫杉类联合新辅助化疗治疗早期或局部晚期乳腺癌的疗效及对患者ER、PR和Her-2的影响[J].中国生化药物杂志,2017,37(3):195-197.
[9]周晓芳,王增,李楚倩.乳腺癌新辅助化疗前后ER、PR、Ki-67和Her-2变化[J].中国妇幼健康研究,2016,27(3):320-322.
[10]田艳芹,刘鲁英,张玉.新辅助化疗对局部进展期乳腺癌患者Cerb-2、Ki-67表达的影响[J].中国继续医学教育,2016,8(3):96-97.
[11]金萍艳.紫杉类联合蒽环类方案新辅助化疗治疗乳腺癌的近期疗效观察[J].中国社区医师,2017,33(14):47-48.
[12]肖秀兰,任统伟.蒽环类为主序贯紫杉类新辅助化疗方案治疗三阴乳腺癌的临床观察[J].实用癌症杂志,2017,32(6):907-909.
[13]李林海.线粒体DNA突变与乳腺癌风险相关性研究[D].广州:南方医科大学,2015.
[14]金光华,范莹,李子豪.乳腺癌新辅助化疗前后激素受体变化对术后内分泌治疗的影响[J].中国现代普通外科进展,2017,20(1):22-26.
[15]Li ML,Dong Y,Luan SL,et al.Changes of expression of estrogen and progestrone receptors,human epithelial growth factor receptor 2 and Ki-67 after neoadjuvant chemotherapy in the treatment of breast cancer[J].J Biol Regul Homeost Agents,2016,30(4):1059-1065.
[16]Qin Q,Gao F,Jiang W,et al.Effect of neoadjuvant chemotherapy on expressions of estrogen receptor,progesterone receptor,human epidermal growth factor receptor 2,and Ki-67 in breast cancer[J].Chin Med J(Engl),2014,127(18):3272-3277.
[17]王红梅,张晖,张京雪.新辅助化疗对乳腺癌患者ER PR P53 cerb-B-2 Ki-67表达的影响[J].安徽医学,2014,35(6):724-726.
[18]Salim DK,Mutlu H,Eryilmaz MK,et al.Molecular types and neoadjuvant chemotherapy in patients with breast cancer-while molecular shifting is more common in luminal a tumors,the pathologic complete response is most frequently observed in her-2 like tumors[J].Asian Pac J Cancer Prev,2014,15(21):9379-9383.
[19]Lim SK,Lee MH,Park IH,et al.Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome[J].Cancer Res Treat,2016,48(1):133-141.
[20]Zhou X,Zhang J,Yun H,et al.Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer:tumorheterogeneity should be taken into consideration[J].Oncotarget,2015,6(34):36894-36902.
[21]Avci N,Deligonul A,Tolunay S,et al.Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor,progesterone receptor,HER2,and Ki-67 in patients with breast cancer[J].J BUON,2015,20(1):45-49.
[22]Shuai Y,Ma L.Prognostic value of pathologic complete response and the alteration of breast cancerimmunohistochemical biomarkers after neoadjuvant chemotherapy[J].Pathol Res Pract,2019,215(1):29-33.
[23]陈圣,黄焰,王也,等.新辅助化疗对浸润性乳腺癌分子标志物及分子分型的影响[J].中华损伤与修复杂志(电子版),2017,12(2):113-117.
[24]Xian Z,Quinones AK,Tozbikian G,et al.Breast cancer biomakers befor and after neoadjuvant chemotherapy:does repeat testing impact therapeutic management[J].Hum Pathol,2017,62:215-221.
[25]王文彦,张柏林,徐晓洲,等.新辅助化疗后腋窝淋巴结分期和病理缓解状态对乳腺癌患者预后的影响[J].中华肿瘤杂志,2015,37(3):195-199.
[26]侯芃芬,丁芳,江时建,等.ERα及PR在乳腺癌患者中的表达及与疾病预后关系探讨[J].中国现代医生,2017,55(7):5-7.
[27]Jin G,Han Y,Liu C,et al.Evaluation of biomarker changes after administration of various neoadjuvantchemotherapies in breast cancer[J].Int J Clin Exp Pathol,2015,8(1):914-921.
[28]Nishimukai A,Yagi T,Yanai A,et al.High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer[J].Clin Breast Cancer,2015,15(3):204-211.
[29]Sivasanker M,Sistla SC,Manwar SA,et al.Clinical and pathologic response following taxane based neoadjuvantchemotherapy in locally advanced breast cancer patients in a tertiary care centre in India[J].Indian J Cancer,2016,53(2):220-225.
[30]Ge WK,Yang B,Zuo WS,et al.Evaluation of hormone receptor,human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancerpatients[J].Thorac Cancer,2015,6(1):64-69.
[2]Catsburg C,Miller AB,Rohan TE.Adherence to cancer prevention guidelines and risk of breast cancer[J].Int J Cancer,2014,135(10):2444-2452.
[3]Aytekin A,Karatas F,Sahin S,et al.Clinicopathological features of patients with breast cancer aged 70 years or over[J].J BUON,2017,22(1):200-207.
[4]Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CACancer J Clin,2016,66(1):7-30.
[5]卢玮冬,许震,陆筱灵,等.培美曲塞联合顺铂治疗经蒽环类和紫杉类一线治疗失败的晚期转移性乳腺癌的疗效观察[J].国际肿瘤学杂志,2014,41(10):797-798.
[6]Wahler J,Suh N.Targeting HER2 positive breast cancer with chemopreventive agents[J].Curr Pharmacol Rep,2015,1(5):324-335.
[7]Petrelli F,Viale G,Cabiddu M,et al.Prognostic value of different cutt-off levels of Ki-67 in breast cancer:a systematic review and metaanalysis of 64,196 patients[J].Breast Cancer Res Treat,2015,153(3):477-491.
[8]吕锋,黄小娥,鲁科斌.蒽环类与紫杉类联合新辅助化疗治疗早期或局部晚期乳腺癌的疗效及对患者ER、PR和Her-2的影响[J].中国生化药物杂志,2017,37(3):195-197.
[9]周晓芳,王增,李楚倩.乳腺癌新辅助化疗前后ER、PR、Ki-67和Her-2变化[J].中国妇幼健康研究,2016,27(3):320-322.
[10]田艳芹,刘鲁英,张玉.新辅助化疗对局部进展期乳腺癌患者Cerb-2、Ki-67表达的影响[J].中国继续医学教育,2016,8(3):96-97.
[11]金萍艳.紫杉类联合蒽环类方案新辅助化疗治疗乳腺癌的近期疗效观察[J].中国社区医师,2017,33(14):47-48.
[12]肖秀兰,任统伟.蒽环类为主序贯紫杉类新辅助化疗方案治疗三阴乳腺癌的临床观察[J].实用癌症杂志,2017,32(6):907-909.
[13]李林海.线粒体DNA突变与乳腺癌风险相关性研究[D].广州:南方医科大学,2015.
[14]金光华,范莹,李子豪.乳腺癌新辅助化疗前后激素受体变化对术后内分泌治疗的影响[J].中国现代普通外科进展,2017,20(1):22-26.
[15]Li ML,Dong Y,Luan SL,et al.Changes of expression of estrogen and progestrone receptors,human epithelial growth factor receptor 2 and Ki-67 after neoadjuvant chemotherapy in the treatment of breast cancer[J].J Biol Regul Homeost Agents,2016,30(4):1059-1065.
[16]Qin Q,Gao F,Jiang W,et al.Effect of neoadjuvant chemotherapy on expressions of estrogen receptor,progesterone receptor,human epidermal growth factor receptor 2,and Ki-67 in breast cancer[J].Chin Med J(Engl),2014,127(18):3272-3277.
[17]王红梅,张晖,张京雪.新辅助化疗对乳腺癌患者ER PR P53 cerb-B-2 Ki-67表达的影响[J].安徽医学,2014,35(6):724-726.
[18]Salim DK,Mutlu H,Eryilmaz MK,et al.Molecular types and neoadjuvant chemotherapy in patients with breast cancer-while molecular shifting is more common in luminal a tumors,the pathologic complete response is most frequently observed in her-2 like tumors[J].Asian Pac J Cancer Prev,2014,15(21):9379-9383.
[19]Lim SK,Lee MH,Park IH,et al.Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome[J].Cancer Res Treat,2016,48(1):133-141.
[20]Zhou X,Zhang J,Yun H,et al.Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer:tumorheterogeneity should be taken into consideration[J].Oncotarget,2015,6(34):36894-36902.
[21]Avci N,Deligonul A,Tolunay S,et al.Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor,progesterone receptor,HER2,and Ki-67 in patients with breast cancer[J].J BUON,2015,20(1):45-49.
[22]Shuai Y,Ma L.Prognostic value of pathologic complete response and the alteration of breast cancerimmunohistochemical biomarkers after neoadjuvant chemotherapy[J].Pathol Res Pract,2019,215(1):29-33.
[23]陈圣,黄焰,王也,等.新辅助化疗对浸润性乳腺癌分子标志物及分子分型的影响[J].中华损伤与修复杂志(电子版),2017,12(2):113-117.
[24]Xian Z,Quinones AK,Tozbikian G,et al.Breast cancer biomakers befor and after neoadjuvant chemotherapy:does repeat testing impact therapeutic management[J].Hum Pathol,2017,62:215-221.
[25]王文彦,张柏林,徐晓洲,等.新辅助化疗后腋窝淋巴结分期和病理缓解状态对乳腺癌患者预后的影响[J].中华肿瘤杂志,2015,37(3):195-199.
[26]侯芃芬,丁芳,江时建,等.ERα及PR在乳腺癌患者中的表达及与疾病预后关系探讨[J].中国现代医生,2017,55(7):5-7.
[27]Jin G,Han Y,Liu C,et al.Evaluation of biomarker changes after administration of various neoadjuvantchemotherapies in breast cancer[J].Int J Clin Exp Pathol,2015,8(1):914-921.
[28]Nishimukai A,Yagi T,Yanai A,et al.High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer[J].Clin Breast Cancer,2015,15(3):204-211.
[29]Sivasanker M,Sistla SC,Manwar SA,et al.Clinical and pathologic response following taxane based neoadjuvantchemotherapy in locally advanced breast cancer patients in a tertiary care centre in India[J].Indian J Cancer,2016,53(2):220-225.
[30]Ge WK,Yang B,Zuo WS,et al.Evaluation of hormone receptor,human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancerpatients[J].Thorac Cancer,2015,6(1):64-69.